SCHEMBL2362969

SCHEMBL2362969

COCCN1CCN(C(=O)c2cc(OC)c(C(C)(C)C)cc2-c2ccc[nH]c2=O)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 9/20 0.42
ALDH1A1 P00352 1/20 0.41
MAPK14 Q16539 1/20 0.41
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
CCR8 P51685 1/20 0.39
KCNH2 Q12809 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
DRD2 P14416 5/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HPGDS O60760 1/20 0.38
TLR9 Q9NR96 1/20 0.38
TLR8 Q9NR97 1/20 0.38
TLR7 Q9NYK1 1/20 0.38
KCNA5 P22460 1/20 0.38
MGLL Q99685 1/20 0.37
ADRB1 P08588 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3309855 0.87 HSP90AA1 (0.40) ALDH1A1MAPK14POLBCCR8KCNH2
SCHEMBL2362947 0.84 NPC1 (0.43) ALDH1A1GAANPC1RAB9AKMT2A
SCHEMBL2361926 0.83 CCR8 (0.38) ALDH1A1MAPK14CCR8KCNH2KMT2A
SCHEMBL3348570 0.83 CCR8 (0.43) ALDH1A1MAPK14CCR8KCNH2KMT2A
SCHEMBL2362966 0.81 HCRTR1 (0.36) GAACCR8KCNH2HPGDSMGLL
SCHEMBL2350049 0.80 LPAR5 (0.42) ALDH1A1MAPK14CCR8KCNH2KMT2A
SCHEMBL2362914 0.80 NPC1 (0.38) ALDH1A1MAPK14GAACCR8KCNH2
SCHEMBL3314653 0.79 SPR (0.41) ALDH1A1MAPK14GAACCR8KCNH2
SCHEMBL2361756 0.78 JAK2 (0.42) GAACCR8KCNH2
SCHEMBL2350724 0.77 NAPRT (0.43) ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US claimed
EP-2350007-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-08-03 EP claimed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US claimed
WO-2010049331-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B DRD3 1674/4885ALDH1A1 861/4885MAPK14 3877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.